FindTrial
Sign In

It is a comparison between a combination of Bilastine with Montelukast and Fexofenadine with Montelukast in Allergic Rhinitis.

Bilastine with Montelukast and Fexofenadine with Montelukast in Allergic Rhinitis: A Randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047305
Enrollment
182
Registered
2022-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Bilastine with Montelukast: Bilastine and Montelukast of dose 20mg and 10mg respectively will be given orally for 1 month in patients of Allergic Rhinitis Control Intervention1: Fexofen

Sponsors

ROHILKHAND MEDICAL COLLEGE AND HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients willing to participate in this study. All patients including both the gender above the age of 18 years. All cases having symptom of Allergic Rhinitis.

Exclusion criteria

Exclusion criteria: Female patients during Pregnancy and Lactation. Patients with Hypertensive Heart Disease, Diabetes Mellitus, Throid Dysfunction. Patients with nasal mass. Patients with past history of nasal surgery.

Design outcomes

Primary

MeasureTime frame
Efficacy of Bilastine with Montelukast and Fexofenadine with Montelukast in the treatment of Allergic Rhinitis.Timepoint: 0, 2 and 4 weeks—

Secondary

MeasureTime frame
Symptom free duration.Timepoint: 0, 2 and 4 weeks—

Countries

India

Contacts

Public ContactSWATI PRASAD

ROHILKHAND MEDICAL COLLEGE AND HOSPITAL

drabhinavsrivastava7@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026